CM
VRDN icon

Caption Management’s Viridian Therapeutics VRDN Stock Holding History

Caption Management’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-40,000
Closed -$559K – 2068
2025
Q2 		$559K Buy
40,000
+7,300
+22% +$99.1K 0.01% 1085
2025
Q1 		$441K Sell
32,700
-71,900
-69% -$1.22M ﹤0.01% 1126
2024
Q4 		$2.01M Sell
104,600
-87,400
-46% -$1.9M 0.02% 687
2024
Q3 		$4.37M Buy
+192,000
New +$3.14M 0.07% 332
2024
Q2 		– Sell
-45,000
Closed -$788K – 1540
2024
Q1 		$788K Buy
+45,000
New +$872K 0.01% 790
2023
Q3 		– Sell
-92,200
Closed -$2.19M – 1570
2023
Q2 		$2.19M Buy
92,200
+42,200
+84% +$1.08M 0.04% 478
2023
Q1 		$1.27M Buy
+50,000
New +$1.6M 0.02% 569
2022
Q2 		– Sell
-36,000
Closed -$665K – 1861
2022
Q1 		$665K Hold
36,000
– – 0.01% 1092
2021
Q4 		$713K Hold
36,000
– – 0.01% 1156
2021
Q3 		$592K Buy
+36,000
New +$528K 0.01% 1173

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Caption Management's VRDN Position: Q2 2026 in Review

Caption Management increased its Viridian Therapeutics (VRDN) stake by 91% in Q2 2026, buying an estimated $659K and bringing the position to 86,040 shares worth $1.58M. The position accounts for 0.01% of the portfolio, ranked #981.

Caption Management first reported a position in VRDN in Q2 2022 and has held it in 9 quarters since. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Caption Management held 86,040 shares of Viridian Therapeutics worth $1.58M as of Q2 2026.
  • Caption Management bought 40,913 Viridian Therapeutics shares in Q2 2026, an estimated $659K.
  • Viridian Therapeutics made up 0.01% of Caption Management's portfolio in Q2 2026, its #981 holding.
  • Caption Management first reported a position in Viridian Therapeutics in Q2 2022 and has held it in 9 quarters since.
  • 214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Caption Management's 13F filing for Q2 2026, filed 14 Aug 2026.